false 0000910267 0000910267 2024-01-11 2024-01-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report: January 11, 2024

(Date of earliest event reported)

 

TITAN PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-13341   94-3171940

(State or other jurisdiction of

incorporation)

  

(Commission File

Number)

   (IRS Employer
Identification No.)

 

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

 

650-244-4990

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   TTNP   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 11, 2024, Brian Crowley gave notice of his resignation as Senior Vice President, Finance and Administration of Titan Pharmaceuticals, Inc. (the “Company”), effective February 2, 2024. Mr. Crowley served as the Company’s principal accounting officer. Our board of directors has initiated a search process for a new principal accounting officer. Mr. Crowley will continue to assist the Company through February 2, 2024 in order to ensure a successful transition.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
104   Cover Page Interactive Data (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TITAN PHARMACEUTICALS, INC.
     
  By: /s/ David E. Lazar
   

David E. Lazar

    Chief Executive Officer

 

Date: January 18, 2024

 

2

 

v3.23.4
Cover
Jan. 11, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 11, 2024
Entity File Number 001-13341
Entity Registrant Name TITAN PHARMACEUTICALS, INC.
Entity Central Index Key 0000910267
Entity Tax Identification Number 94-3171940
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 400 Oyster Point Blvd.
Entity Address, Address Line Two Suite 505
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 244-4990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TTNP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Titan Pharmaceuticals Charts.
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Titan Pharmaceuticals Charts.